Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multicenter, randomized, double-blind, comparative study to evaluate the safety and efficacy of ceftaroline [ceftaroline fosamil] versus ceftriaxone in the treatment of adult subjects with community-acquired pneumonia.

Next Previous
X
Search
Trial Profile

A phase 3, multicenter, randomized, double-blind, comparative study to evaluate the safety and efficacy of ceftaroline [ceftaroline fosamil] versus ceftriaxone in the treatment of adult subjects with community-acquired pneumonia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Ceftriaxone
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS-2; FOCUS-II
  • Sponsors Cerexa; Forest Laboratories

    • Most Recent Events

    • 28 Dec 2018 Results assessing safety and tolerability of ceftaroline fosamil q8h and q12h regimens using data from 6 phase three trials (NCT01499277, NCT00424190, NCT00423657, NCT01371838, NCT00621504 and NCT00509106) published in the Journal of Antimicrobial Chemotherapy
    • 24 Apr 2018 Results assessing comparison of safety profile of two regimens of ceftaroline fosamil by using data from six phase III studies (COVERS, CANVAS 1, CANVAS 2, FOCUS 1, FOCUS 2, and asian CAP) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 05 Jun 2017 Results of subgroup analysis from two phase III studies (FOCUS-1 and FOCUS-2) presented at the ASM Microbe 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top